2024 was a transformative year for Spermosens. The company implemented a revised strategy centered on generating strong clinical evidence for JUNO-Checked – its unique and patented diagnostic technology – while shifting its commercial approach to partnership and license-based models.

Key achievements included the launch of a clinical study with faster-than-expected recruitment and a second interim analysis confirming a clear correlation between JUNO binding and fertilization outcome. At the same time, Spermosens improved operational efficiency, secured new strategic investors and extended its financial runway into 2026. The share issue subscribed in March 2025 for SEK 10.8 million has not yet been registered or disbursed, as the company is awaiting a decision from the Swedish Inspectorate of Strategic Products (ISP) before registration can take place.

With a strengthened foundation and growing partner interest, Spermosens is now well positioned to complete the clinical study, advance its technology and pursue licensing agreements in key markets.

For further information, please contact:
Tore Duvold, CEO
E-mail: info@spermosens.com

Spermosens AB is a pioneering biotechnology company dedicated to advancing fertility treatments through innovative diagnostic solutions. Based in Sweden, Spermosens specializes in developing cutting-edge technologies that improve fertility outcomes and simplify the treatment process for individuals and couples facing infertility challenges. The proprietary JUNO-Checked product aims to enhance the precision and effectiveness of fertility diagnostics, ultimately helping more people achieve their dream of parenthood. Committed to scientific excellence and patient care, Spermosens collaborates with leading research institutions and commercial partners to bring transformative solutions to the market. The company's shares are listed on the Spotlight Stock Market. The shares have ISIN code SE0015346424 and are traded under the short name SPERM. For more information, see www.spermosens.com